SCHEMBL2087783

SCHEMBL2087783

[CH2]/C=C/c1ccc2c(c1)OCO2

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.67
ATM Q13315 1/20 0.67
CYP19A1 P11511 2/20 0.62
HSD17B10 Q99714 2/20 0.60
ALDH1A1 P00352 2/20 0.60
TDP1 Q9NUW8 1/20 0.60
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
MTOR P42345 1/20 0.57
VCP P55072 1/20 0.57
CYP1A2 P05177 2/20 0.54
PGR P06401 1/20 0.53
AR P10275 1/20 0.53
GABRA1 P14867 1/20 0.53
MAOA P21397 1/20 0.53
SLC6A2 P23975 1/20 0.53
PDE4A P27815 1/20 0.53
KDR P35968 1/20 0.53
GABRB2 P47870 1/20 0.53
SLC6A3 Q01959 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2087784 1.00 CYP3A4 (0.67) CYP3A4ATMCYP19A1HSD17B10ALDH1A1
SCHEMBL2094647 0.88 KDM4E (0.59) CYP3A4ATMCYP19A1HSD17B10ALDH1A1
SCHEMBL2094645 0.88 KDM4E (0.59) CYP3A4ATMCYP19A1HSD17B10ALDH1A1
SCHEMBL19472000 0.87 CYP19A1 (0.78) CYP3A4ATMCYP19A1HSD17B10ALDH1A1
SCHEMBL29108872 0.81 CYP3A4 (0.62) CYP3A4ATMCYP19A1HSD17B10ALDH1A1
SCHEMBL28837107 0.80 CYP3A4 (0.67) CYP3A4ATMCYP19A1HSD17B10ALDH1A1
Isosafrole SCHEMBL345862 0.80 CYP3A4 (1.00) CYP3A4ATMCYP19A1HSD17B10ALDH1A1
Isosafrole SCHEMBL30302237 0.80 CYP3A4 (1.00) CYP3A4ATMCYP19A1HSD17B10ALDH1A1
SCHEMBL7977301 0.80 CYP3A4 (0.67) CYP3A4ATMCYP19A1HSD17B10ALDH1A1
Isosafrole SCHEMBL7075676 0.80 CYP3A4 (1.00) CYP3A4ATMCYP19A1HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112939778-B Coumarin compound ester derivatives, preparation method and application thereof 西北农林科技大学 2022-08-02 CN claimed
CN-112939778-A Coumarin compound ester derivatives, preparation method and application thereof 西北农林科技大学 2021-06-11 CN claimed
US-20080076817-A1 Small Molecule Rotamase Enzyme Inhibitors HAMILTON GREGORY S 2008-03-27 US claimed
EP-1227859-B1 NEUROPHILIN LIGANDS FOR TREATING OCULAR CONDITIONS ALCON INC (CH) 2006-08-09 EP claimed
US-6943187-B2 Pyrrolidine derivative hair growth compositions and uses GPI NIL HOLDINGS, INC. (US) 2005-09-13 US claimed
US-20040186098-A1 Method for preventing and treating hearing loss using sensorineurotrophic compounds AMGEN INC. 2004-09-23 US claimed
US-20040049046-A1 Small molecule inhibitors of rotamase enzyme activity GPI NIL HOLDINGS, INC. (US) 2004-03-11 US claimed
US-20020198250-A1 Pyrrolidine derivative hair growth compositions and uses GLIAMED, INC. 2002-12-26 US claimed
US-20010049381-A1 Pyrrolidine derivative hair growth compositions and uses GPL NIL HOLDINGS, INC., 2001-12-06 US claimed
US-20010034362-A1 Pyrrolidine derivatives for vision and memory disorders GUILFORD PHARMACEUTICALS INC. (US) 2001-10-25 US claimed
US-6239164-B1 IMMUNOPHILIN AFFINITY; NONIMMUNOSUPPRESSANT GPI NIL HOLDINGS, INC. 2001-05-29 US claimed
US-6218423-B1 ADMINISTERING PYRROLIDINE DERIVATIVE FOR THERAPY OF NERVE-RELATED VISION DISORDER, IMPROVING VISION, TREATING MEMORY IMPAIRMENT, OR ENHANCING MEMORY PERFORMANCE IN ANIMAL GPI NIL HOLDINGS, INC. 2001-04-17 US claimed
US-6177455-B1 ADMINISTERING A NITROGEN-CONTAINING HETEROCYCLIC COMPOUND GPI NIL HOLDINGS, INC. 2001-01-23 US claimed
EP-0769006-B1 SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY GUILFORD PHARM INC (US) 2000-11-08 EP claimed
EP-1011650-A1 METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS Amgen Inc., (US) 2000-06-28 EP claimed
EP-0992492-A1 Small molecule inhibitors of rotamase enzyme activity GUILFORD PHARMACEUTICALS INC. (US) 2000-04-12 EP claimed
WO-1999014998-A2 METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS AMGEN INC. (US) 1999-04-01 WO claimed
US-5614547-A Small molecule inhibitors of rotamase enzyme GUILFORD PHARMACEUTICALS INC. (US) 1997-03-25 US claimed
WO-1996040633-A9 SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY 1997-02-27 WO claimed
WO-1996040633-A1 SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 1996-12-19 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186098-A1 Method for preventing and treating hearing loss using sensorineurotrophic compounds GAP43, CHAT, MYOC CYP3A4 4866/4885ATM 3476/4885CYP19A1 4544/4885
US-20040049046-A1 Small molecule inhibitors of rotamase enzyme activity FKBP8, FKBP14, PREP CYP3A4 3357/4885ATM 4791/4885CYP19A1 2463/4885
US-20020198250-A1 Pyrrolidine derivative hair growth compositions and uses MKI67, PLOD2, HDGF CYP3A4 2089/4885ATM 4611/4885CYP19A1 171/4885
US-20010034362-A1 Pyrrolidine derivatives for vision and memory disorders PDE6D, PDE6C, PDE4D CYP3A4 3462/4885ATM 3530/4885CYP19A1 3357/4885
US-20080076817-A1 Small Molecule Rotamase Enzyme Inhibitors FKBP8, FKBP1A, FKBP2 CYP3A4 3508/4885ATM 4798/4885CYP19A1 2303/4885
US-20010049381-A1 Pyrrolidine derivative hair growth compositions and uses MKI67, PLOD2, HDGF CYP3A4 2089/4885ATM 4611/4885CYP19A1 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.